eBook

Discover what’s on the horizon for the pharma industry as truly transformative technologies revolutionize the way drugs are developed, delivered and manufactured.

With the pharmaceutical industry still adjusting to the potential impacts of Humira's loss of exclusivity, another milestone for biosimilars has been achieved in 2022.

As we enter the third year of the COVID-19 pandemic, the pharma industry has begun to adapt and grow around its constraints and opportunities.

With AbbVie less than a year away from losing patent exclusivity on its innovative $20.7 billion monoclonal antibody product Humira ® (gross sales in 2021), the United States (US) market is about to change significantly.

Before the pandemic, most people outside the life sciences sector would likely be unfamiliar with mRNA.

It was a real pleasure to host the 17th Annual Scrip Awards and honor the many achievements of the pharmaceutical, biotechnology, clinical research and allied sectors.